David Mott Biography and Net Worth

Director of IMARA

David M. Mott has served as a member of Imara’s board of directors since January 2016. Mr. Mott is a private investor through Mott Family Capital. From September 2008 to February 2020, Mr. Mott was general partner at New Enterprise Associates (“NEA”) and led the healthcare investing practice.

Prior to joining NEA, Mr. Mott was President and Chief Executive Officer of MedImmune, a biotechnology company. He joined MedImmune in 1992 and served in various roles, including president and chief executive officer from October 2000 through July 2008 and previously Chief Financial Officer and President and Chief Operating Officer. Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Earlier in his career, he was a Vice President in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc.

Mr. Mott currently serves on the boards of several public biotechnology companies, including Adaptimmune (ADAP), Ardelyx (ARDX), Epizyme (EPZM), Novavax (NVAX) and Mersana (MRSN). Mr. Mott earned a B.A. in government and economics from Dartmouth College.

What is David M. Mott's net worth?: The estimated net worth of David M. Mott is at least $0.00 as of December 19th, 2024. Mr. Mott owns 1,638,765 shares of IMARA stock worth more than $0 as of December 25th. This net worth estimate does not reflect any other investments that Mr. Mott may own. Learn More about David M. Mott's net worth.
How do I contact David M. Mott?: The corporate mailing address for Mr. Mott and other IMARA executives is 116 HUNTINGTON AVENUE. 6TH FLOOR, BOSTON MA, 02116. IMARA can also be reached via email at [email protected]. Learn More on David M. Mott's contact information.
Has David M. Mott been buying or selling shares of IMARA?: David M. Mott has not been actively trading shares of IMARA in the last ninety days. Most recently, on Tuesday, February 22nd, David M. Mott bought 16,454 shares of IMARA stock. The stock was acquired at an average cost of $6.24 per share, with a total value of $102,672.96. Learn More on David M. Mott's trading history.

David M. Mott Insider Trading History at IMARA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/22/2022	Buy	16,454	$6.24	$102,672.96
2/18/2022	Buy	12,599	$5.20	$65,514.80
2/16/2022	Buy	2,944	$4.80	$14,131.20
2/14/2022	Buy	2,125	$4.72	$10,030.00
2/10/2022	Buy	2,188	$5.16	$11,290.08

David M. Mott Buying and Selling Activity at IMARA

IMARA Company Overview

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $17.12

$6.32

$25.28

2 Week Range

Now: N/A

Volume

271,700 shs

Average Volume

138,364 shs

Market Capitalization

$165.80 million

P/E Ratio

126.40

Dividend Yield

N/A

Beta

1.09

Vladimir Lenin was right…

From Porter & Company | Ad

Including the name of the #1 company to buy.